Fig. 3:From: An observational, non-interventional study for the follow-up of patients with amyloidosis who received miridesap followed by dezamizumab in a phase 1 study6MWD over time by patient. Dashed line, cardiac involvement; solid line, no cardiac involvement. 6MWD, 6-min walking distance; AA, serum amyloid A; ApoAI, apolipoprotein A-I; AFib, fibrinogen-a alpha chain; AL, immunoglobulin light chain; ATTR, transthyretinBack to article page